劲方医药-B:2025 年中期报告

香港交易所
Sep 30, 2025

牛牛AI助手已提取核心信息劲方医药科技(上海)股份有限公司公布2025年中期业绩。期内收入为8,874万元人民币,净亏损扩大至6.986亿元人民币,去年同期亏损4.493亿元。研发成本为1.2244亿元人民币,较去年同期1.86亿元下降34.2%,主要由于去年同期产生终止中国境外选择权及专利许可协议费用。公司核心产品GFH925(达伯特®)已于2024年8月获国家药监局批准上市,成为中国首款及全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10